Analysts Expect Novo Nordisk A/S (NVO) Will Announce Earnings of $0.61 Per Share
Wall Street analysts forecast that Novo Nordisk A/S (NYSE:NVO) will post earnings of $0.61 per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Novo Nordisk A/S’s earnings. Novo Nordisk A/S reported earnings per share of $0.62 during the same quarter last year, which would indicate a negative year-over-year growth rate of 1.6%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, November 7th.
On average, analysts expect that Novo Nordisk A/S will report full-year earnings of $2.52 per share for the current financial year, with EPS estimates ranging from $2.49 to $2.55. For the next financial year, analysts expect that the firm will report earnings of $2.56 per share, with EPS estimates ranging from $2.50 to $2.61. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that cover Novo Nordisk A/S.
A number of research analysts have weighed in on the stock. Sanford C. Bernstein raised shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research report on Monday, July 2nd. Zacks Investment Research raised shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research report on Tuesday, July 31st. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $64.00.
Novo Nordisk A/S stock opened at $47.87 on Wednesday. The firm has a market cap of $114.53 billion, a price-to-earnings ratio of 20.46, a PEG ratio of 2.52 and a beta of 0.66. Novo Nordisk A/S has a fifty-two week low of $44.28 and a fifty-two week high of $58.37.
The company also recently announced a special dividend, which will be paid on Tuesday, August 28th. Shareholders of record on Monday, August 20th will be given a dividend of $0.4669 per share. This represents a yield of 1.72%. The ex-dividend date of this dividend is Friday, August 17th. Novo Nordisk A/S’s dividend payout ratio is 38.89%.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.
Further Reading: Leveraged Buyout (LBO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.